EP Patent

EP4551554A1 — Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors

Assigned to Chiesi Farmaceutici SpA · Expires 2025-05-14 · 1y expired

What this patent protects

The present invention generally relates to compounds inhibiting dipeptidyl peptidase 1 activity; particularly the invention relates to compounds that are azetidine derivatives, including pharmaceutically acceptable salts thereof, methods of preparing such compounds, and therapeut…

USPTO Abstract

The present invention generally relates to compounds inhibiting dipeptidyl peptidase 1 activity; particularly the invention relates to compounds that are azetidine derivatives, including pharmaceutically acceptable salts thereof, methods of preparing such compounds, and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DPP1 receptors mechanisms, in particular respiratory diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP4551554A1
Jurisdiction
EP
Classification
—
Expires
2025-05-14
Drug substance claim
No
Drug product claim
No
Assignee
Chiesi Farmaceutici SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.